Production (Stage)
Citius Pharmaceuticals, Inc.
CTXR
$0.703
-$0.021-2.90%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 19.75% | 26.00% | 37.32% | 59.00% | 50.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.91% | 9.97% | 14.33% | 20.24% | 13.68% |
| Operating Income | -9.91% | -9.97% | -14.33% | -20.24% | -13.68% |
| Income Before Tax | -19.66% | -5.78% | -21.53% | -27.50% | -18.31% |
| Income Tax Expenses | 41.74% | 20.87% | 0.00% | -42.86% | -33.33% |
| Earnings from Continuing Operations | -20.01% | -6.01% | -21.15% | -25.18% | -16.87% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.16% | -3.92% | -20.27% | -25.18% | -16.87% |
| EBIT | -9.91% | -9.97% | -14.33% | -20.24% | -13.68% |
| EBITDA | -9.92% | -9.98% | -14.33% | -20.24% | -13.68% |
| EPS Basic | 3.11% | 8.94% | -7.50% | -18.36% | -11.73% |
| Normalized Basic EPS | 10.74% | 3.77% | -3.37% | -10.08% | -4.49% |
| EPS Diluted | 3.95% | 9.57% | -6.30% | -16.49% | -14.87% |
| Normalized Diluted EPS | 10.74% | 3.77% | -3.37% | -10.08% | -4.49% |
| Average Basic Shares Outstanding | 19.95% | 13.46% | 11.16% | 9.87% | 7.87% |
| Average Diluted Shares Outstanding | 19.95% | 13.46% | 11.16% | 9.87% | 7.87% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |